New research on inflammation could lead to better treatments to improve outcomes for people with advanced or previously untreatable cancers.
The findings come as welcome news as NSW lockdowns continue – but future cancer treatment patterns will depend on how current infection rates develop.
Promising research shows scientists can identify a key cancer biomarker – PD-L1 – in blood.
Associate Professor Guozhen Liu has been recognised for breakthroughs in individualised treatment for autoimmune diseases and cancer.
Professor John Whitelock is improving the smarts of antibodies and sending them into the extracellular area to outwit those clever cancer cells.
